Table 2 Characteristics of participants and treatment
Demographic Data | |
|---|---|
Age (years) | |
Mean (standard deviation) | 40,7 (6,2) |
Minimum – Maximum | 30,7–51,4 |
T-stage, n (%) | |
1ª | 2 (7,7) |
1b | 3 (11,5) |
1c | 3 (11,5) |
2 | 12 (46,2) |
3 | 5 (19,2) |
X | 1 (3,8) |
Number of affected lymph nodes, n (%) | |
0 | 5 (19,2) |
0(i+) | 1 (3,8) |
1mi | 3 (11,5) |
1a | 8 (30,8) |
1b | 4 (15,4) |
2a | 3 (11,5) |
2b | 1 (3,8) |
X | 1 (3,8) |
Presence of metastasis, n (%) | |
No | 23 (88,5) |
Yes | 3 (11,5) |
Surgery, n (%) | |
Yes | 25 (96,2) |
No | 1 (3,8) |
Adjuvant chemotherapy,, n (%) | |
Yes | 22 (84,6) |
No | 4 (15,4) |
Adjuvant chemotherapy regimen, n (%) | |
ACdd + T | 10 (45,5) |
TC x 6 | 5 (22,7) |
AC + T | 1 (4,5) |
Other | 6 (27,3) |
Total | 22 (100,0) |
If other regimen, which one? n (%) | |
ddEC-T | 1 (16,7) |
EC-T | 1 (16,7) |
Taxol–> FEC | 1 (16,7) |
TCH | 1 (16,7) |
TCH x6 | 1 (16,7) |
TCHP adjuvant | 1 (16,7) |
Total | 6 (100,0) |
Adjuvant Hormone Therapy Regimen, n (%) | |
Goserelin + Exemestane | 14 (53,8) |
Goserelin + Letrozole | 9 (34,6) |
Goserelin + Tamoxifen | 1 (3,8) |
Goserelin + Exemestane | 1 (3,8) |
Goserelin + Palbociclib + Anastrozole | 1 (3,8) |
Letrozol | 1 (3,8) |
Received adjuvant radiotherapy, n (%) | |
Yes | 21 (80,8) |
No | 5 (19,2) |